Cellzome Lands Big GSK Deal: €475M for Inflammatory Diseases
LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International)
BioWorld International Correspondent
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST